All In Biotech

Drug Trial Radar · NCT07623798

A Study in Participants With Relapsed or Refractory Multiple Myeloma for IBI3003

A Phase 3 Randomized Study Comparing IBI3003 Versus Treatment Per Investigator's Choice in Participants With Relapsed or Refractory Multiple Myeloma

Last checked: Nov 19, 2026Latest source record: Sep 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 255 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

255

Planned (sponsor's estimate)

Start

Jun 11, 2026

Primary completion

May 31, 2029

Study completion Dec 31, 2029

Sponsor

Sponsor type
Industry
First posted
Jun 3, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate how well IBI3003 works when compared with the investigator's choice regimen (DPd or PVd or SVd)

Conditions

  • Relapsed or Refractory Multiple Myeloma

Interventions

  • Pomalidomide CapsulesDrug

    1. The DPd treatment regimen, one cycle every 28 days: Pomalidomide 4mg/d orally, on days 1-21; 2. The PVd treatment regimen, one cycle every 21 days: Pomalidomide 4 mg/d orally, on days 1-14 of each treatment cycle;

  • Bortezomib for InjectionDrug

    The PVd treatment regimen, with one cycle every 21 days: Bortezomib on days 1, 4, 8, and 11 of cycles 1-8, and on days 1 and 8 from cycle 9 onwards.

  • Daratumumab Injection (Subcutaneous Injection)Drug

    The DPd treatment regimen, one cycle every 28 days: on days 1, 8, 15, and 22 of cycles 1 and 2; on days 1 and 15 from cycles 3-6; and on day 1 from cycle 7 onwards.

  • IBI3003Drug

    According to body weight

  • Selinexor TabletsDrug

    The SVd treatment regimen, with one cycle every 35 days: Bortezomib on days 1, 8,15,22 and 29 ,100 mg/d orally.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. PFS assessed by independent review committeeTime frame: up to 24 months after the last enrolled participant receives the first dose of study drug

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • ZhongShan Hospital FuDan University

    Shanghai, Shanghai Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.